SEC Tracker
Get the app

Verastem VSTM

Verastem reports strong Q3 revenue and CEO transition

Form
8-K
Filed
Importance
Major
  1. Net product revenue for Q3 2026 estimated at $23.9M-$24.1M, up from $11.2M in Q3 2025.
  2. Cash and investments as of Sept 30, 2026 estimated at $172.8M, up from $137.7M as of Sept 30, 2025.
  3. Daniel Paterson to retire as CEO on Jan 1, 2027; Michael Bailey to be appointed as new CEO.
  4. VS-7375 shows 50% confirmed ORR in 2L PDAC and 36% in 3L/4L setting.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Verastem files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025
  2. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  5. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025